Indian stocks: Visit www.stage2stocks.com →

Eocene Ltd.

Stage 4 · Declining · week 17

As of Oct 22, 2026, Eocene is in Stage 4, the downtrend phase, now in week 17 (since Jun 30, 2026). It closed at $3.08, 73.9% below its 52-week high and below its 200-day average, which is falling.

Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. More about the company

$3.08
-1.41% today
$3.3M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is EOCN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 21w
S4 30w
S4 36w
S4 16w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 21w → S1 4w → S4 3w → S1 2w → S4 7w → S1 8w → S4 12w → S1 1w → S2 7w → S3 1w → S4 30w → S1 9w → S4 36w → S1 2w → S4 2w → S1 4w → S4 16w current
Total tracked: 166 weeks across 17 stage runs.

EOCN among Biotechnology438th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…438EOCNStage 4 · wk 1714−15.1%
vs 52W High
-73.9%
$2.85 lo$11.76 hi
73.9% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 17
1w13w26w
Week 17, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-34.5%
200 DMA: $4.69 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.24x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-15.1%
3M
-25.1%
6M
-37.5%
YTD
-53.3%
1Y
-73.1%
Scan Membership
Breakout Watch
Latest: 2024-09-26
4 appearances in last 60 days. First seen: 2020-01-28.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 17 · Vol 0.24x
2026-10-21S4
Wk 16 · Vol 0.24x
2026-10-20S4
Wk 16 · Vol 0.22x
2026-10-19S4
Wk 16 · Vol 0.26x
2026-10-16S4
Wk 16 · Vol 0.38x
2026-10-15S4
Wk 16 · Vol 0.07x
2026-10-14S4
Wk 15 · Vol 0.34x
2026-10-13S4
Wk 15 · Vol 0.31x
2026-10-12S4
Wk 15 · Vol 0.32x
2026-10-09S4
Wk 15 · Vol 0.16x
2026-10-08S4
Wk 15 · Vol 0.50x
2026-10-07S4
Wk 14 · Vol 0.23x
Moving averages & range
50 DMA
$3.73
200 DMA
$4.69
52W High
$11.76
52W Low
$2.85
5D Low
$2.85
Resistance levels (recent highs)
20d High
$3.63
60d High
$4.97
120d High
$6.03
250d High
$11.76
Next resistance
+18.0%
to 20d High
ROE
-68.2%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 0.2

Eocene: quick answers

What stage is Eocene in?

As of Oct 22, 2026, Eocene (EOCN) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 30, 2026 and is in week 17. What the four stages mean

Is Eocene in an uptrend?

No. Eocene is in a Stage 4 downtrend. It trades 34.5% below its 200-day average, which is falling.

How far is Eocene from its 52-week high?

Eocene closed at $3.08 on Oct 22, 2026, 73.9% below its 52-week high of $11.76. Its 52-week low is $2.85.

How has Eocene performed over the past year?

As of Oct 22, 2026, Eocene is down 73.1% over the past year and down 53.3% so far in 2026.

Which sector and industry is Eocene in?

Eocene is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Eocene Ltd. was formerly known as Galmed Pharmaceuticals Ltd. and changed its name to Eocene Ltd. in September 2026. Eocene Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.